References
- Jain H, Schweitzer JW, Justice NA. Respiratory syncytial virus infection in children. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. https://www.ncbi.nlm.nih.gov/books/NBK459215.
- Lee Mortensen G, Harrod-Lui K. Parental knowledge about respiratory syncytial virus (RSV) and attitudes to infant immunization with monoclonal antibodies. Expert Rev Vaccines. 2022 Oct;21(10):1523–9. doi:10.1080/14760584.2022.2108799.
- Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ, Madhi SA, Omer SB, Simões EAF, Campbell H. et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022 May 28;399(10340):2047–64. doi:10.1016/S0140-6736(22)00478-0.
- Gea-Izquierdo E, Gil-Prieto R, Hernandez-Barrera V, Gil-de-Miguel A. Respiratory syncytial virus-associated hospitalization in children aged <2 years in Spain from 2018 to 2021. Hum Vaccin Immunother. 2023 Aug 1;19(2):2231818. doi:10.1080/21645515.2023.2231818.
- Grupo de Trabajo utilización de nirsevimab frente a infección por virus respiratorio sincitial de la Ponencia de Programa y Registro de Vacunaciones. Comisión de Salud Pública del Consejo Interterritorial del Sistema Nacional de Salud. Ministerio de Sanidad, julio; 2023 [accessed 2023 Nov]. https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/comoTrabajamos/docs/Nirsevimab.pdf.
- Rosas-Salazar C, Chirkova T, Gebretsadik T, Chappell JD, Peebles RS Jr., Dupont WD, Jadhao SJ, Gergen PJ, Anderson LJ, Hartert TV. et al. Respiratory syncytial virus infection during infancy and asthma during childhood in the USA (INSPIRE): a population-based, prospective birth cohort study. Lancet. 2023 May 20;401(10389):1669–80. doi:10.1016/S0140-6736(23)00811-5.
- Sigurs N, Gustafsson PM, Bjarnason R, Lundberg F, Schmidt S, Sigurbergsson F, Kjellman B. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med. 2005 Jan 15;171(2):137–41. doi:10.1164/rccm.200406-730OC.
- Del Riccio M, Spreeuwenberg P, Osei-Yeboah R, Johannesen CK, Fernandez LV, Teirlinck AC, Wang X, Heikkinen T, Bangert M, Caini S, et al. RSV in Europe: estimates of RSV-associated hospitalisations in children under 5 years of age. A systematic review and modelling study. medRxiv. 2023. doi:10.1101/2023.02.10.23285756.
- Wildenbeest JG, Billard MN, Zuurbier RP, Korsten K, Langedijk AC, van de Ven PM, Snape MD, Drysdale SB, Pollard AJ, Robinson H. et al. The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study. Lancet Respir Med. 2023 Apr;11(4):341–53. doi:10.1016/S2213-2600(22)00414-3.
- Gil-Prieto R, Gonzalez-Escalada A, Marin-Garcia P, Gallardo-Pino C, Gil-de-Miguel A. Respiratory syncytial virus bronchiolitis in children up to 5 years of age in Spain: Epidemiology and comorbidities: an observational study. Medicine (Baltimore). 2015 May;94(21):e831. doi:10.1097/MD.0000000000000831.
- Heppe-Montero M, Walter S, Hernandez-Barrera V, Gil-Prieto R, Gil-de-Miguel Á. Burden of respiratory syncytial virus-associated lower respiratory infections in children in Spain from 2012 to 2018. BMC Infect Dis. 2022 Mar 31;22(1):315. doi:10.1186/s12879-022-07261-1.
- European Medicines Agency (EMA). Synagis, INN-palivizumab summary of product characteristics; 2004. [accessed 2023 Nov]. https://www.ema.europa.eu/en/documents/product-information/synagis-epar-product-information_en.pdf.
- Eiland LS. Respiratory syncytial virus: diagnosis, treatment and prevention. J Pediatr Pharmacol Ther. 2009 Apr;14(2):75–85. doi:10.5863/1551-6776-14.2.75.
- European Medicines Agency (EMA). Product information beyfortus® (nirsevimab); 2022. [accessed 2023 Nov]. https://www.ema.europa.eu/en/documents/product-information/beyfortus-eparproduct-information_es.pdf.
- Jones JM, Fleming-Dutra KE, Prill MM, Roper LE, Brooks O, Sanchez PJ, Kotton CN, Mahon BE, Meyer S, Long SS. et al. Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the advisory committee on immunization practices — United States, 2023. MMWR Morb Mortal Wkly Rep. 2023 Aug 25;72(34):920–5. doi:10.15585/mmwr.mm7234a4.
- Haute Autorité de Santé. Nirsévimab (Beyfortus®) dans la prévention des bronchiolites à virus respiratoire syncytial (VRS) chez les nouveau-nés et les nourrissons; 2023. [accessed 2024 Apr]. https://www.has-sante.fr/jcms/p_3461236/fr/nirsevimab-beyfortus-dans-la-prevention-des-bronchiolites-a-virus-respiratoire-syncytial-vrs-chez-les-nouveau-nes-et-les-nourrissons.
- Le Gouvernement Luxembourgeois. Nouvelle immunisation pour se protéger de la bronchiolite pour les nourrissons et jeunes enfants; 2023. [accessed 2024 Apr]. https://gouvernement.lu/fr/actualites/toutes_actualites/communiques/2023/09-septembre/22-immunisation-bronchiolite-nourrissons.html#:~:text=%C3%80%20partir%20de%202024%2C%20tous,de%20haute%20circulation%20du%20RSV.
- Clark LA, Watson D. Constructing validity: New developments in creating objective measuring instruments. Psychol Assess. 2019 Dec;31(12):1412–27. doi:10.1037/pas0000626.
- Ruckwardt TJ. The road to approved vaccines for respiratory syncytial virus. NPJ Vaccines. 2023 Sep 25;8(1):138. doi:10.1038/s41541-023-00734-7.
- MurciaSalud [Internet]. Sistema de Vigilancia de Infección Respiratoria Aguda en Atención Primaria. Región de Murcia: Temporada 2022–2023; 2024. [accessed 2024 Apr]. https://www.murciasalud.es/documents/128166/6091445/Vigilancia+de+infecci%C3%B3n+respiratoria+leve+en+Atenci%C3%B3n+Primaria+IRA-AP.+Informaci%C3%B3n+metodol%C3%B3gica.pdf/240218a4-82e1-d54f-7cd6-5cae63555121?t=1700048914558.
- Martinon-Torres F, Miras-Carballal S, Duran-Parrondo C. Early lessons from the implementation of universal respiratory syncytial virus prophylaxis in infants with long-acting monoclonal antibodies, Galicia, Spain, September and October 2023. Euro Surveill. 2023 Dec;28(49):2300606. doi:10.2807/1560-7917.ES.2023.28.49.2300606.
- MurciaSalud [Internet]. Virus respiratorio sincitial - VRS; 2022. [accessed 2024 Apr]. https://www.murciasalud.es/documents/5435832/5545872/Coberturas+provisionales+de+inmunizaci%C3%B3n+con+Nirsevimab.pdf/30328cba-aa1e-6e35-7770-b22e98f8c35f?t=1711099482261.
- Bell S, Clarke R, Mounier-Jack S, Walker JL, Paterson P. Parents’ and guardians’ views on the acceptability of a future COVID-19 vaccine: A multi-methods study in England. Vaccine. 2020 Nov 17;38(49):7789–98. doi:10.1016/j.vaccine.2020.10.027.
- Takagi MA, Hess S, Smith Z, Gawronski K, Kumar A, Horsley J, Haddad N, Noveloso B, Zyzanski S, Ragina N. et al. The impact of educational interventions on COVID-19 and vaccination attitudes among patients in Michigan: a prospective study. Front Public Health. 2023;11:111144659. doi:10.3389/fpubh.2023.1144659.
- Tang S, Liu X, Jia Y, Chen H, Zheng P, Fu H, Xiao Q. Education level modifies parental hesitancy about COVID-19 vaccinations for their children. Vaccine. 2023 Jan 9;41(2):496–503. doi:10.1016/j.vaccine.2022.11.060.
- Daniels D, Imdad A, Buscemi-Kimmins T, Vitale D, Rani U, Darabaner E, Shaw A, Shaw J. Vaccine hesitancy in the refugee, immigrant, and migrant population in the United States: a systematic review and meta-analysis. Hum Vaccin Immunother. 2022 Nov 30;18(6):2131168. doi:10.1080/21645515.2022.2131168.
- Dube E, Gagnon D, Nickels E, Jeram S, Schuster M. Mapping vaccine hesitancy–country-specific characteristics of a global phenomenon. Vaccine. 2014 Nov 20;32(49):6649–54. doi:10.1016/j.vaccine.2014.09.039.
- Kennedy A, Lavail K, Nowak G, Basket M, Landry S. Confidence about vaccines in the United States: understanding parents’ perceptions. Health Aff (Millwood). 2011 June;30(6):1151–9. doi:10.1377/hlthaff.2011.0396.
- Ministerio de Sanidad. Número de profesionales de la medicina que trabajan en el Sistema Nacional de Salud (SNS) en Atención Primaria, Atención Hospitalaria, Servicios de urgencias y emergencias (112/061) y Especialistas en formación según comunidad autónoma; 2022. [accessed 2024 Apr]. https://www.sanidad.gob.es/estadEstudios/sanidadDatos/tablas/tabla13.htm.
- Ricco M, Corrado S, Cerviere MP, Ranzieri S, Marchesi F. Respiratory syncytial virus prevention through monoclonal antibodies: a cross-sectional study on knowledge, attitudes, and practices of Italian pediatricians. Pediatr Rep. 2023 Feb 20;15(1):154–74. doi:10.3390/pediatric15010013.